Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Clin Genitourin Cancer. 2023 Feb 28:S1558-7673(23)00043-5. doi: 10.1016/j.clgc.2023.02.010

Table 4.

ADA incidence by cohort

Cohort Dose ADA-positive/Total Patients
1 IV 0.1 μg/kg 0/1
2 IV 0.3 μg/kg 0/3
3 IV 1 μg/kg 0/3
4 IV 3 μg/kg 2/5
5 SC 3 μg/kg 2/3
6 SC 10 μg/kg 4/6
7 SC 30 μg/kg 3/4
8 SC 10 then 30 μg/kg 3/5
9 SC 10 then 55 μg/kg 2/5
10 SC 5 and 20, then 60 μg/kg 3/4

ADA, anti-drug-antibodies; IV, intravenous; SC, subcutaneous.